COVID-19：米国でアビガンの臨床試験開始：マサチューセッツ州3病院:
COVID-19:Clinical Trials for Avigan Started in the US:3 Massachusetts Hospitals：
COVID-19：Avigan的临床试验在美国开始：马萨诸塞州3家医院
COVID-19：米国
富士フイルムホールディングス（HD）：
4月9日、新型インフルエンザ治療薬「アビガン」について、｢米国で新型コロナ感染症患者/臨床試験（治験）を、開始する｣と、発表しました。
近く投与を開始し、有効性や安全性を確認する。
試験は、ブリガム・アンド・ウイメンズ病院など、米国のマサチューセッツ州にある3施設で行なわれます。
感染が広がっている米国での早期承認を、目指す。
共同通信
https://this.kiji.is/620885809076421729
Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for COVID-19 patients in the U.S.
TOKYO, April 9, 2020
FUJIFILM announces the initiation of a U.S. phase II clinical trial
to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.
Avigan, approved in Japan for manufacture and sale as an influenza antiviral drug,
selectively inhibits RNA polymerase necessary for influenza virus replication.
Due to this mechanism of action, it is expected that Avigan may potentially have an antiviral effect on the new coronavirus,
because like influenza viruses, coronaviruses are single-stranded RNA viruses that also depend on viral RNA polymerase.
On March 31, Fujifilm announced the start of a phase III clinical trial of Avigan for COVID-19 patients in Japan.
The clinical trial in the U.S.
will enroll approximately 50 patients with COVID-19,
in collaboration with
- Brigham and Women’s Hospital,
- Massachusetts General Hospital, and
- the University of Massachusetts Medical School.
Fujifilm will continue to work to establish a treatment method for COVID-19 patients through conducting clinical trials,
and to contribute to ending the spread of this global pandemic as soon as possible by increasing the production of Avigan in collaboration with strategic partners.
Fujifilm Global